mutations supplied the fact that, as described under, CLL therapy relies around the presence or absence of those mutations. The current consensus is always that, besides clonal mutations, subclonal mutations having a variant allelic frequency ranging from 5 to 10% (and thus below the threshold of detection by regular molecular tactics) could also b